Unmet Needs in the Treatment of RA in the Era of Jak-i: IDRA (Italian Delphi Rheumatoid Arthritis) Consensus
Table 4
Answers to the Delphi questionnaire. (Items 7 and 8). The table shows the Delphi questionnaire and the answers relating to the individual items. The answers given by the Delphi participants are expressed in numerical terms. The percentages indicate the sum of the answers related to nonconsensus (1, 2) and consensus (3, 4, and 5).
treatment adherence
7. Adherence to DMARD is often suboptimal in RA patients. Poor adherence can reduce the effectiveness of any treatment. Therefore I believe that the factors that can influence therapeutic adherence are:
1
2
3
4
5
7.1 A shared decision between doctor and patient about drug treatment
1
1
1
14
31
4
96
7.2 The mode of administration of the drug
0
3
14
19
12
6
94
7.3 The frequency of administration of the drug
1
3
15
16
13
8
92
7.4 Rapid improvement of symptoms
1
2
5
13
27
6
94
7.5 Side effects
1
0
4
15
28
2
98
7.6 Patient involvement in specific programs
1
4
18
11
14
10
90
Prognostic factors for treatment response
8. There are no clear prognostic factors for response to therapies. in the choice of treatment I rely on:
1
2
3
4
5
8.1 Patient’s Phenotypic characteristics: age, sex, concomitant therapies, body mass index and life habits
0
0
8
22
18
0
100
8.2 The presence of any comorbidity
1
0
2
15
30
2
98
8.3 The prevalent biological pathway to choose the most suitable MoA drug by searching for specific biomarkers (SNPs, micro-RNA, polymorphisms, etc.)
5
14
12
11
6
40
60
8.4 The possible presence of anti-drug antibodies if the patient is a secondary failure
6
17
9
10
6
48
52
8.5 The MOA of biological drugs administered before
0
5
9
18
16
10
90
Abbreviations. DMARD: disease-modifying antirheumatic drug; RA: rheumatoid arthritis; MoA: mechanism of action; SNPs: single nucleotide polymorphism; RNA: ribonucleic acid.
